| DC10563 |
E-7046
Featured
|
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
|
| DC5065 |
Golvatinib (E7050)
Featured
|
E-7050 is hepatocyte growth factor receptors (HGFR). |
|
| DC8488 |
LENVATINIB MESYLATE
Featured
|
E7080 (Lenvatinib) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. |
|
| DC7116 |
E7080 (Lenvatinib)
Featured
|
E7080 (Lenvatinib; Vargatef) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. |
|
| DC21898 |
E7090 succinate |
E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM). |
|
| DC22085 |
Tasurgratinib（E7090)
Featured
|
E7090 (E 7090) is a highly potent and selective orally bioavailable inhibitor targeting FGFR1, FGFR2, and FGFR3, with IC50 values of 0.71 nM, 0.50 nM, and 1.2 nM, respectively. It exhibits significantly weaker inhibition of FGFR4, with an IC50 of 120 nM. This distinct selectivity profile positions E7090 as a promising therapeutic candidate for diseases driven by aberrant FGFR1-3 signaling, offering a targeted approach to inhibit these receptors while minimizing off-target effects on FGFR4. Its oral availability further enhances its potential as a convenient and effective treatment option for patients with FGFR-dependent conditions. |
|
| DC11062 |
E7107 |
E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo. |
|
| DC10976 |
E-7386
Featured
|
E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively. |
|
| DC9983 |
E-7449
Featured
|
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors. |
|
| DC10784 |
E7820
Featured
|
E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells. |
|
| DC9665 |
EAI045
Featured
|
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. |
|
| DCAPI1441 |
Seocalcitol |
EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca |
|
| DC11037 |
EB-3D |
EB-3D is a novel potent and selective choline kinase ChoKα inhibitor with IC50 of 1.0 uM (purified ChoKα1), strongly impairs cell proliferation in a variety of different cancer cell lines. |
|
| DC9534 |
EBE-A22
Featured
|
EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.
|
|
| DC20989 |
EBI-1051 |
EBI-1051 is a novel and orally efficacious MEK inhibitor with IC50 of 10.8 nM against MEK1, inhibits viability of colo-205 cells with IC50 of 4.7 nM. |
|
| DC11477 |
EBI-2511
Featured
|
EBI-2511 is a highly potent and orally active EZH2 inhibitor for the treatment of Non-Hodgkin’s Lymphoma. |
.gif)
|
| DC23818 |
EBI-907 |
EBI-907 is a highly potent, selective, orally active B-Raf V600E inhibitor with enzyme IC50 of 7 nM, A375 cell growth IC50 of 13 nM. |
|
| DC9848 |
Ebselen
Featured
|
Ebselen is a selenium-based inhibitor of protein kinase C, NADPH, 5-lipoxygenase, cyclooxygenase (COX) and NADPH oxidase. |
|
| DC20123 |
EC0489 |
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor. Small molecule-drug conjugate (SMDC). |
|
| DC10277 |
EC330
Featured
|
EC330 is a leukemia inhibitory factor (LIF) inhibitor. |
|
| DC10980 |
EC-359 |
EC-359 (EC359) is a first-in-class, orally available inhibitor of leukemia inhibitory factor (LIF), blocks LIF-LIFR interaction and binds to LIFR with affinity of 81 nM in SPR assay. |
|
| DC20990 |
EC-70124 |
EC-70124 is a multikinase inhibitor with potent activity against several AML related kinases including FLT3, JAK, SYK or Pim kinases (Kd<10 nM). |
|
| DC26057 |
Ecabet (sodium salt)
Featured
|
Ecabet is an antiulcerative and gastroprotective agent. |
|
| DCAPI1162 |
Ecdysone |
Ecdysone |
|
| DCAPI1408 |
Echinocandin B0 |
Echinocandin B0 |
|
| DC9912 |
Echinocystic acid
Featured
|
Echinocystic acid a pentacyclic triterpene isolated from the fruits of Gleditsia sinensis Lam, has potent antioxidant, anti-inflammatory and anti-tumor properties. |
|
| DCAPI1126 |
Econazole nitrate (Spectazole) |
Econazole nitrate (Spectazole) |
|
| DC21514 |
Ecopladib |
Ecopladib (PLA 725) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 0.15 and 0.11 uM in GLU micelle and rat whole blood assays, respectively. |
|
| DC10400 |
Ecteinascidin 770 |
Ecteinascidin 770 (ET-770) is a 1,2,3,4-tetrahydroisoquinoline alkaloid with potent anti-cancer activities; inhibits U373MG cells with an IC50 of 4.83 nM. |
|
| DCAPI1380 |
Edaravone (MCI-186) |
Edaravone (MCI-186) |
|
